Market Research Report Store Non-Hodgkin Lymphoma-API Insights, 2017-Market Res | Page 2

The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources
information and data has been collected from various printable and non-printable sources like search
engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade
associations, Books, Industry Portals, Industry Associations and access to available databases.
Scope
• A snapshot of the global Market therapeutics scenario for Non-Hodgkin Lymphoma.
• A review of the marketed products under prescription for Non-Hodgkin Lymphoma, regulatory
information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across
the globe.
• Product profiles for marketed products for Non-Hodgkin Lymphoma with complete description of
mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Non-Hodgkin Lymphoma drugs in the United States, Europe and
Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for
Non-Hodgkin Lymphoma drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2012-2016.Reasons to Buy
• Evaluate the marketing status and exclusivity details of Non-Hodgkin Lymphoma key products to
exploit opportunities for generic drug development opportunities.
• Key players in the pharmaceutical industry.
•Strategic drivers and restraints of this market are revealed and market opportunities and challenges are
identified.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry
details and exclusivity with respect to Non-Hodgkin Lymphoma.
• API intelligence over marketed drugs for Non-Hodgkin Lymphoma and gaining primary intelligence
over active ingredients manufacturers across the globe.